【摘要】 目的探讨β受体阻滞剂与血管紧张素Ⅱ受体阻滞剂(ARB)联合治疗慢性心力衰竭(CHF)的疗效。方法给予基础心脏病治疗和心衰的常规治疗,β受体阻滞剂组加β受体阻滞剂,ARB组加ARB,ARB+β受体阻滞剂组加ARB和β受体阻滞剂。结果在改善心脏结构和心功能,减少住院次数和心率,ARB+β受体阻滞剂组疗效优于β受体阻滞剂组和ARB组,差异均有统计学意义(P<0.05)。结论β受体阻滞剂与ARB联合治疗CHF,能更好地预防心脏重构,改善心功能,减少CHF患者临床事件的发生。更多还原

【Abstract】 【Objective】To study the effect of β-receptor blockers and angiotensin Ⅱ blockers(ARB)in the treatment of chronic heart failure(CHF)patients.【Methods】Each group is given basic treatment of heart disease and conventional treatment of heart failure.The β-receptor blocker group and ARB group and ARB + β-receptor blocker group are respectively given β-receptor blocker agent,ARB agent,β-receptor blocker agent and ARB agent.【Results】 The effect in improving the cardiac structure and cardiac function and reducing the number of hospitalization and heart rate of ARB + β-receptor blocker group is better than that of the β-receptor blocker group and the ARB group,and the differences were statistically significant(P <0.05).【Conclusion】ARB + β-receptor blocker in the treatment of CHF can well prevent heart remodeling and improve cardiac function and reduce occurrence of clinical events in patients with CHF.更多还原